Inhibition of the ternary protein complex of the synaptic scaffolding protein postsynaptic density protein-95 (PSD-95), neuronal nitric oxide synthase (nNOS), and the N-methyl-D-aspartate (NMDA) receptor is a potential strategy for treating ischemic brain damage, but high-affinity inhibitors are lacking. Here we report the design and synthesis of a novel dimeric inhibitor, Tat-NPEG4(IETDV) 2 (Tat-N-dimer), which binds the tandem PDZ1-2 domain of PSD-95 with an unprecedented high affinity of 4.6 nM, and displays extensive protease-resistance as evaluated in vitro by stability-measurements in human blood plasma. X-ray crystallography, NMR and smallangle X-ray scattering (SAXS) deduced a true bivalent interaction between dimeric inhibitor and PDZ1-2, and also provided a dynamic model of the conformational changes of PDZ1-2 induced by the dimeric inhibitor. A single intravenous injection of Tat-N-dimer (3 nmol/g) to mice subjected to focal cerebral ischemia reduces infarct volume with 40% and restores motor functions. Thus, Tat-N-dimer is a highly efficacious neuroprotective agent with therapeutic potential in stroke. 
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A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage
Results
Design and activity of novel dimeric inhibitors
We have previously demonstrated that the five C-terminal amino acids of GluN2B are sufficient for maintaining wild-type binding affinity towards the individual PDZ1 (K i = 14 µM) and PDZ2
(K i = 3 µM) domains (19) . Thus, by linking two pentapeptides (IETAV) with a mono-disperse polyethylene glycol (PEG) linker of optimal length, a high-affinity dimeric ligand, PEG4(IETAV) 2 (O-dimer) (Fig. 1B ), is obtained with K d (mean ± SEM) of 9.8 ± 1.6 nM towards tandem PDZ1-2 of PSD-95 (20, 21) . We here redesigned the PEG linker, and synthesized a novel PEG-based linker, termed NPEG (Scheme S1A), where the central oxygen of the PEG4 linker is replaced by nitrogen, which upon linkage with two IETAV moieties provides NPEG4(IETAV) 2 (N-dimer) (Fig. 1B) . In order to improve permeability across the blood-brain barrier, we attached the cell-penetrating peptide sequences, Tat and its inverse D-amino acid-containing version
Retroinverso-D-Tat (22) , to the linker nitrogen, and used IETDV as ligand moiety, which is more selective than IETAV towards PDZ1 and PDZ2 over PDZ3 (20) . This resulted in dimeric ligands
Tat-NPEG4(IETDV) 2 (Tat-N-dimer) and Retroinverso-D-Tat-NPEG4(IETDV) 2 (ReTat-N-dimer) (Fig. 1B, Scheme S1B, and Fig. S1 ).
For in vitro affinity evaluation we developed a revised fluorescence polarization assay, where we prepared fluorescently (5-FAM, F) labeled N-dimer (F-N-dimer, Fig. S1 ) and used it as a high-affinity probe (K d ; mean ± SEM: 7.8 ± 0.1 nM). This allowed us to determine accurate K i values for high-affinity ligands in a simple and fast format (20, 23) . Tat-N-dimer and ReTat-Ndimer displayed affinities (K i ; mean ± SEM) of 4.6 ± 0.3 and 5.1 ± 0.4 nM, respectively, against PDZ1-2 of PSD-95, whereas N-dimer bound PDZ1-2 with an affinity (K i ; mean ± SEM) of 9.3 ± 1 nM ( Fig. 2A) . Tat-N-dimer is thereby by far the most potent PDZ domain inhibitor described (15, (24) (25) (26) , and provides a 1,000-fold increase in affinity relative to monomeric Tat-NR2B9c
(K i ; mean ± SEM: 4,600 ± 300 nM, Fig. 2A ).
A general concern of peptide-based compounds is their susceptibility to enzymatic cleavage in biological fluids and tissues. Monomeric pentapeptide IETDV and Tat-NR2B9c
showed half-lives (T 1/2 ; mean ± SEM) of 37 ± 6 and 1,100 ± 300 minutes in human blood plasma in vitro, respectively, while Tat-N-dimer had a T 1/2 (mean ± SEM) of 4,900 ± 100 minutes ( Fig.   2A ), thus having >100 fold improved stability compared to IETDV. Hence, the combination of 6 dimerization and attachment of cell-penetrating peptides has a striking positive effect on protease stability. Further, no detectable degradation was observed for ReTat-N-dimer within the period of measurements, demonstrating the effect of incorporating D-amino acids into the cell-penetrating peptide sequence ( Fig. 2A) . 
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To test the effect of introducing cell-penetrating peptides on the permeability of the bloodbrain barrier, the ligands were labeled with 5-FAM (F) and injected intravenously in mice (3 nmol/g). Fluorescence microscopy of coronal brain slices revealed that F-Tat-N-dimer, F-ReTat-N-dimer, and F-Tat-NR2B9c resulted in a strong uniform fluorescence throughout the brain including layer I-VI of the frontal cortex, as compared to sections from F-N-dimer and saline treated mice (Fig. 2B) . Thus blood-brain barrier permeability of the dimeric compounds is obtained by introduction of Tat or ReTat (7) .
Dimeric inhibitor bivalently interacts with PDZ1-2, leading to a flexible and extended conformation
Previous kinetic and mutational studies have suggested that a dimeric ligand binds to PDZ1-2 in a two-step process, where initial binding to either of the two PDZ domains is followed by an intramolecular step leading to the bidentate complex (21) . In order to provide structural evidence for such a genuine dimeric binding mode, where both PDZ domains are occupied by the peptide moieties from the same dimeric ligand, and to gain insight into the molecular details and dynamics of the binding mode, we elucidated the molecular mode of action of our dimeric ligands. First, the domain orientation of the two PDZ domains in apo PDZ1-2 was determined by X-ray crystallography, which, however, showed that the two binding sites face approximately 180° away from each other in an extended conformation that cannot accommodate the dimeric ligands ( Fig. 3A and Table S1 ). Therefore, we prepared a labeled dimeric ligand, [ 15 N, 13 C]-Odimer, and subjected it to structural in solution NMR studies. In an HSQC spectrum of the dimeric, symmetrical ligand alone, five peaks were observed, whereas ten different peaks appeared when the ligand was incubated with PDZ1-2 (Fig. 3B) . From secondary structural calculations based on the chemical shifts for the bound and unbound labeled dimeric ligand, we observed that the unbound ligand exhibits random coil character, while the bound ligand adopts a -stranded structure (Fig. 3C) . Thus, the two peptide moieties of the dimeric ligand face different protein environments (PDZ1 and PDZ2) and β-strand character of the peptide moieties is imposed by binding to PDZ1-2 similar to a canonical PDZ-peptide binding mode (27) .
The dynamic properties of PDZ1-2 upon ligand binding were revealed by calculating correlation times for molecular tumbling of PDZ1 and PDZ2 in PDZ1-2 in complex with O-8 dimer based on R 1 and R 2 relaxation rate measurements. This gave correlation times slightly larger and with less deviation (14.6 and 13.6 ns for PDZ1 and PDZ2, respectively, Table S2 ). Hence, these values suggest that the interdomain motion of PDZ1-2 is only slightly more restricted in complex with dimeric ligand than with a monomeric ligand, while unbound PDZ1-2 is essentially rigid. C]-O-dimer bound to PDZ1-2 (red bars) as calculated using the program SSP. A value of one indicates a fully formed -helix and a value of minus one indicates a fully extended structure whereas a value close to zero is indicative of a random coil. (D) Pair distance distribution functions derived from Fourier transformation of the SAXS data presented as the relative occurrence of distances (arbitrary scale) against distances in nm. Data from apo PDZ1-2 (green), PDZ1-2 with monomeric ligand (IETAV) (blue), and PDZ1-2 with dimeric ligand (Odimer) (gray) are shown. The average radius of the two PDZ domains is visible as the first major peak (around 2 nm, PDZ1 and PDZ2 have similar radii), and the distance between the center of mass of PDZ1 and PDZ2 is seen as the second peak. 
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To further examine the structural changes in PDZ1-2 upon ligand binding, we performed small angle X-ray scattering (SAXS) studies of PDZ1-2. In apo PDZ1-2, a distinct distance of approximately 3.3 nm is observed (Fig. 3D) , which likely represents the average distance between PDZ1 and PDZ2 when no ligand is bound to the protein. Interestingly, this distance increases upon binding of O-dimer (3.6 nm) and even more upon binding of monomeric ligand IETAV (3.9 nm) (Fig. 3D and Table S3 ). This demonstrates that the closed and compact apo PDZ1-2 becomes more extended when the dimeric ligand binds, and even further extended by the monomeric ligand, as visualized by low-resolution ab initio models of the O-dimer and IETAV PDZ1-2 complexes (Fig. 3E) . The two PDZ domains can be located within the Odimer/PDZ1-2 ab initio model, which differs from other reported PDZ1-2 conformations (Fig.   S2 ), by energy minimization so that O-dimer bivalently binds to PDZ1-2, and the peptide moieties of O-dimer interact with each PDZ domain in a canonical manner (Fig. 3F-G ). In conclusion, the SAXS and NMR studies unambiguously demonstrate that the dimeric ligand spans the distance between individual domains, interacts with the PDZ domains in a canonical binding mode, and induces a conformation of PDZ1-2 that is more extended and flexible than unbound PDZ1-2, but more compact and restricted compared to PDZ1-2 in complex with monomeric ligand.
Tat-N-dimer protects against ischemic brain damage in mice
Encouraged by the remarkably high affinity of Tat-N-dimer towards PSD-95 and its stability in blood plasma, we examined Tat-N-dimer as a potential in vivo active neuroprotectant. We tested Tat-N-dimer as well as Tat-NR2B9c and O-dimer in the permanent middle cerebral artery occlusion (pMCAO) model of focal ischemia in adult mice (29) . Compounds were injected (3 nmol/g) once, intravenously, 30 minutes after the pMCAO insult, followed by a 6 hour postsurgical survival period (Fig. 4A) . Animals receiving Tat-N-dimer showed a 40% reduction in ischemic tissue damage compared to saline-treated animals (p = 0.0081) (Fig. 4B ), whereas treatment with O-dimer gave no neuroprotective effect (p = 0.62, N = 19), indicating the necessity for introducing cell-penetrating peptides into the dimeric ligands to obtain effects in vivo. Treatment with Tat-NR2B9c did not provide a statistically significant reduction in infarct volumes (Fig. 4B ) (p = 0.22), although we verified by immunofluorescence employing a primary anti-Tat antibody that both Tat-N-dimer and Tat-NR2B9c were located inside neuron-like cells (30) 6 hours after pMCAO (Fig. 4C) . To evaluate prolonged effects of Tat-N-dimer, we performed the pMCAO experiment with a 48 hour post-surgical survival period (Fig. 4A) and observed a 37% reduction in infarct size compared to saline-treated mice (p = 0.0042) (Fig. 4D-E) . Again, Tat-NR2B9c gave no statistically significant infarct reductions (p = 0.89) (Fig. 4D-E) , but treating animals with ReTat-N-dimer under similar conditions led to a 34% reduction in infarct volumes (p = 0.0094) (Fig.   S3 ). Body temperature, weight and blood gas parameters were monitored during the pMCAO experiment and no differences were observed among the treated groups (Fig. S4 and Table S4 ).
Focal cerebral ischemia induced by pMCAO in mice affects cortical brain areas controlling the contralateral front-and hind-limb including the paws (31) . Thus, we included behavioral tests that challenged the motor function of mice subjected to pMCAO. In accordance with reduced infarct volumes, the total grip strength of both paws was unaffected for animals treated with Tat-N-dimer, but reduced for those given saline or Tat-NR2B9c (Fig. 4F) . Similarly, there was no difference in grip strength between the right and left front paw for Tat-N-dimer-treated animals in contrast to treatment with saline or Tat-NR2B9c (Fig. 4G) . Finally, in the rotarod performance test we observed that Tat-N-dimer resulted in a more pronounced short-term learning skill improvement than saline-treated mice (Fig. 4H) , and the total time spent on the rod was significantly longer (83.5 ± 4.1 seconds; average of trial 1-4 ± SEM) than for mice treated with Tat-NR2B9c (65.7 ± 3.7 seconds; average of trial 1-4 ± SEM) (P<0.001). The effects on motor control of ReTat-N-dimer were similar to those observed for Tat-N-dimer (Fig. S3 ).
Discussion
PSD-95 is a potential target for protection against ischemic brain damage (9), and recent studies demonstrate promising effects of PSD-95 inhibitors in animal models of pain (10-12) and Alzheimer's disease (13) . Despite this intriguing role of PSD-95, there is a lack of inhibitors against PSD-95, and PDZ domains in general, with reasonably affinity and in vivo activity, which impede the possibilities for exploiting PDZ domains as drug targets. Here we have advanced the concept of dimeric inhibitors against the tandem PDZ1-2 domain of PSD-95 in order to develop potent in vivo active ligands. Previously, two decapeptides targeting PDZ1 and PDZ2 have been linked via disulphide bonds from N-terminal cysteine residues, which resulted in 5-20 fold increase in affinity relative to the monomeric ligand (24) , and a related design with peptide sequences of 15 amino acids resulted in a similar 8-25 fold increase in affinity (25) . In the present work, the dimeric ligands provide a remarkable 400-fold increase in affinity compared to the monomeric peptide. This has been achieved by optimizing peptide length and sequence as well as the linker length, and in particular, by the essential modification of changing the PEG linker into NPEG, which allows cell-penetrating peptides to be attached to the dimeric structure without compromising binding affinities. Tat-N-dimer displays an unprecedented high affinity for any PDZ domain-mediated interaction with a K i value of 4.6 nM, which is a 1,000-fold improvement compared to Tat-NR2B9c. In addition, our design provides a solution to the inherent problem of peptides being degraded in biological fluids, as Tat-N-dimer, and in particular ReTat-N-dimer, demonstrates greatly enhanced stability in blood plasma. Moreover, both compounds cross the blood-brain barrier in mice and demonstrate significant in vivo neuroprotective properties, hence Tat-N-dimer reduces ischemic stroke damage in mice with 40% and significantly improves motor functions.
We observe that the high-affinity compounds, Tat-N-dimer and ReTat-N-dimer, are more efficient in vivo neuroprotectants in the mouse pMCAO model compared to the low-affinity monomeric inhibitor Tat-NR2B9c, which did not show statistical significant infarct reductions.
Tat-NR2B9c has previously shown promising effects in both transient and permanent focal ischemic stroke models in rats (7, 8, 16 ), but these studies cannot be directly compared to the current mouse study due to experimental differences (32) . It is, however, noteworthy that under the same conditions and dosages in mice, we see superior activity of the dimeric inhibitors relative to Tat-NR2B9c. Whether this represents generally improved neuroprotective properties across species and types of ischemic stroke models needs confirmation by future studies. In addition, the permanent MCAO model induces a smaller ischemic penumbra than the transient MCAO model in the acute phase after stroke (<4-6 hours after arterial occlusion) where neuroprotection is believed to be achievable (33, 34) . As a result of this, large percentages of rescued tissues are harder to obtain in the permanent model. Hence, a 40% infarct reduction in a permanent model as a result of a single post-stroke administration of Tat-N-dimer is highly promising, and its relevance is underlined by the concomitant improvement in motor functions and persistency after 48 hours (32).
13
To elucidate the mode of action at the molecular level of the dimeric ligands we applied a combination of X-ray crystallography, NMR and SAXS. Previous NMR studies suggest that apo PDZ1-2 of PSD-95 adopts a closed and rigid conformation (24) , in agreement with the C-shaped arrangement of full-length PSD-95 observed by electron microscopy (35) , and that the interdomain mobility of PDZ1 and PDZ2 is increased upon monomeric peptide binding, leading to a flexible and more extended peptide-bound conformation (28) . Based on these observations, it was suggested that this increased conformational freedom of PDZ1-2 upon ligand binding provides extra conformational entropy, which facilitates ligand binding (28) . This intriguing model initially seemed contradictory to the fact that our dimeric ligands display such a large affinity-increase compared to monomeric compounds, as one would expect dimeric ligands to rigidify PDZ1-2 and hence lead to a large entropy penalty. However, our NMR and SAXS studies provide unambiguous evidence for apo PDZ1-2 to be compact and rigid compared to when PDZ1-2 is bound to monomeric compound where it is more extended and flexible.
Moreover, these studies demonstrate that dimeric ligand, although it does make PDZ1-2 more compact relative to monomeric ligand, still facilitates interdomain flexibility of PDZ1-2 to about the same extent as monomeric ligand, thus potentially allowing the conformational entropy of PDZ1-2 to be increased. This could also explain the pronounced difference in affinity of the different types of dimeric inhibitors of PSD-95. We have used very flexible NPEG or PEG-based linkers to dimerize the peptide ligands, whereas other dimeric ligands are less flexible (24, 25) and might therefore be paying a higher entropic penalty, leading to decreased affinity, due to rigidifying PDZ1-2.
PDZ domains generally work as structural and functional modules in neuronal scaffolding and adaptor proteins, and frequently appear as tandem supramodular domains, similar to PDZ1-2 of PSD-95 (36) . The dimeric design presented here is in principle applicable to any protein containing a tandem PDZ domain. Thus, by linking appropriate peptide ligands using the NPEG linker and attachment of cell-penetrating peptides, the methodology demonstrated here is a versatile and straightforward way of generating in vivo active tool compounds and potential therapeutics for proteins containing tandem PDZ domains and even for other bi-modular targets.
In summary, we have designed and synthesized dimeric ligands that are highly efficient inhibitors of the tandem PDZ1-2 domain of the scaffolding protein PSD-95. Tat-N-dimer binds PDZ1-2 with unprecedented high affinity, displays extensive stability in blood plasma, crosses the blood-brain barrier, reduces ischemic stroke damage in mice with 40% and improves motor functions. Using biophysical methods, we have provided unequivocal evidence for a bivalent binding mechanism and characterized the conformational changes upon ligand binding. Tat-Ndimer is at present the most efficient PSD-95 inhibitor described, and could become a valuable pharmacological tool for studying PSD-95-related biology and for paving the way for dimeric PSD-95 inhibitors as drug candidates.
Experimental Procedures
Complete descriptions of ligand synthesis and characterization, protein purification, affinity and stability in vitro assays, X-ray crystallography, NMR, SAXS, modeling, and in vivo experiments are found in SI Experimental Procedures.
7.
Aarts 
Synthesis of F-Tat-N-dimer, F-ReTat-N-dimer, F-Tat-NR2B9c and F-N-dimer.
O-dimer by the on-resin dimerization method used for the synthesis of O-dimer, as described previously (2).
Expression and purification of PDZ1-2 of PSD-95.
For X-ray and NMR studies, PDZ1-2 (residues 61-249, referring to the residue numbers in the human full-length PSD95α without exon 4b, Uniprot accession number P78352) was produced as previously described (3). Uniformly 
X-ray crystallography of PDZ1-2 of PSD-95.
For X-ray studies, PDZ1-2 preparations with intact His-tag were used as previously described Table S1 . Diffraction data were obtained on microfocus beamline ID23-2, ESRF, Grenoble France. Due to radiation damage, a full dataset (44 frames) was assembled from four data collections on the same crystal but translated to different regions.
The data were indexed and scaled to 3.4 Å resolution using MOSFLM (5) and SCALA (6) within CCP4 (7, 8) . The protein crystallized in the space group P4 1 2 1 2 with four molecules in the asymmetric unit. The structure was solved using the molecular replacement program PHASER (9) within CCP4 with a search model generated by the program BALBES (10). The generated model was based on the X-ray structure of SAP-102-PDZ1 (PDB 2I1N). The amino acid sequence of the search models had been changed to that of PSD-95 PDZ2 and side chains of long flexible residues as Lys, Arg and Glu were truncated. Flexible loops and the C-and N-terminal 8 ends were also truncated. From the first search using PHASER, four domains were identified.
Visual examination showed that these four domains were well-defined by the electron density, and well-defined electron density was also observed in the unmodeled regions of the linkers and loops. The identified domains were fixed when searching for additional domains in the following molecular replacement runs. Also, the percentage cut-off used for selection in the rotation search was lowered to 65, 60 and 55%, respectively. In this manner, solutions for seven domains in total were identified. The last domain (PDZ1 of molecule D) was also localized in the molecular replacement search, but the electron density in several areas around this was very poor compared to the other domains. In the final molecular replacement solution clear difference electron density could be observed in PDZ1-PDZ2 linker regions.
The structure was refined to R work /R free values of 21.9/26.4% and validated using program PHENIX (11) . Before building the unmodeled regions, the structure was refined using a rigidbody refinement scheme. The R free -value was high (40.8%) after this refinement, but as the structure was corrected and the unmodeled regions were built using program COOT (12), R free decreased rapidly. After the rigid-body refinement, the refinement of the structure was continued using combined TLS, B-group and NCS. B-group was selected over B-individual due to the medium resolution of the data and the NCS restraints were important, as the structure was otherwise over-fitted to the data. Between each refinement step every residue was examined in the 2Fo-Fc and Fo-Fc maps and if necessary adjusted. In the initial refinements (up to step 5), PDZ1 and the linker region between PDZ1 and PDZ2 of molecule D were not built due to poor electron density around this domain. Examination of the electron density map (2Fo-Fc) and the omit map (Fo-Fc) in this region revealed well-defined electron density in some areas. Modeling of the linker and parts of the domain resulted in a decrease in R free by ca. 2%. Later, the number of residues to be included in the domain was revised, and refinements revealed that deleting residues with poorly defined side chains did not affect the R free -value. A slight decrease (0.5%) in the difference between the R-values suggested that the structure was less over-fitted to the data in the final structure (step 6) compared to step 5, possibly as a result of the deleted residues in PDZ1 of molecule D between step 5 and 6. In the final structure, the linker of molecule D and the three β-strands: βA, βD and βF of PDZ1 were included in the structure. βA, βD and βF form an antiparallel β-sheet; thus, these residues have several contacts to each other. Polar contacts 9 from these β-strands to other domains in the crystal were also observed, which was not the case for the rest of the domain if it were built. These contacts might induce more order in this part of the domain, which might explain why it is possible to identify βA, βD and βF of molecule D. NMR data were processed using NMRpipe (15) and visualized using Sparky (Goddard and Kneller, University of California at San Francisco). Assignments for the bound and unbound forms of PDZ1-2 were obtained by transferring the assignments from PDZ1-2/cypin (16) and free PDZ1-2 (17), respectively. Since a different compound was used in this study and since sample conditions were different, only slightly more than half of the assignments could be transferred with confidence. The remaining peaks in the spectra were not analyzed. Peaks were integrated and volumes converted into relaxation rates using the in house program PINT (Ahlner A., Carlsson M., Jonsson B.H. and Lundström P., Linköping University; available upon request).
NMR
The same program was used to convert R 1ρ relaxation rates into R 2 relaxation rates. The correlation time for molecular tumbling was estimated from the R 2 /R 1 ratio, excluding residues with NOE<0.65 (18) . The secondary structure for free and bound [ 15 N, 13 C]-O-dimer was calculated with the program SSP (19) .
SAXS studies of PDZ1-2 of PSD-95.
Measurements were done over a range of protein concentrations (0.25-7.1 mg/mL). To ensure full saturation, a 5:1 mixture ratio of ligand:protein were used at all protein concentrations.
SAXS data were collected at beamline ID14-3 at ESRF, Grenoble, France (20) . The automated sample loader was used, applying a continued flow of maximally 40 µL of sample, while applying 10 times 10 seconds of exposures at 8 °C. Individual exposures were radially averaged and compared for potential radiation damage, and those exposures where damage was evident were discarded before averaging. Pure buffer samples were measured before and after the protein samples, and an average of the two data files was used for background subtraction. The primary data reduction was performed using PRIMUS which is part of the ATSAS suite (21) . The molecular mass of the protein complex in the sample was estimated via internal calibration with a bovine serum albumin sample. Radius of gyration was estimated by the Guinier approximation implemented in PRIMUS, and the fourier transformation was calculated using the program GNOM (22) . The program CRYSOL was applied for comparison to the known high-resolution structures (23) . The ab initio modeling program DAMMIF (24) , which is a novel faster implementation of the precursor DAMMIN (25), was implemented for generation of the solution model reconstructions. Ten models were calculated in the slow mode, using standard settings.
The program DAMAVER (26) was applied to superimpose individual structures, and to evaluate the spatial discrepancy between individual models. The averaged and filtered model (available upon request) was used for the visualization in Fig. 3E and Fig. S2 . High-resolution structures were optimally oriented for minimization of spatial discrepancy onto the filtered model by applying the program SUPCOMB (27) .
High-resolution model of the O-dimer/PDZ1-2 complex.
The model of PDZ1-2 in complex with O-dimer (Fig. 3G ) was created by implementing the rigid body modeling program BUNCH, which uses simulated annealing combined with ab initio modeling approaches for determining the optimal position of high-resolution protein domains by fitting these against SAXS data (28) . The NMR based PDZ1-2 model (17) onto the filtered solution structure of PDZ1-2 bound to O-dimer using SUPCOMB (Fig. 3G) , and CRYSOL was applied for comparison of the final high-resolution model and the experimental scattering data giving X = 1.15 (Fig. 3F ).
Mice for in vivo studies.
The permanent middle cerebral artery occlusion (pMCAO) study was performed using age- Group size and study design.
The extent of the ischemic infarct was measured in two separate randomized, double-blinded, placebo controlled studies: 1) Determination of the neuroprotective effects of O-dimer, Tat-Ndimer, and Tat-NR2B9c compared to saline, as evaluated 6 hours after pMCAO; and 2)
Determination of the neuroprotective effects of Tat-N-dimer, ReTat-N-dimer, and Tat-NR2B9c compared to saline, as evaluated 48 hours after pMCAO. In the 6 hour survival study, 82 mice were used, of which 4 died due to anesthesia and 8 were found not to have an infarct and was therefore excluded. In the 48 hour survival study, 82 mice were used, 5 died due to anesthesia and 8 were found not to have an infarct and was therefore excluded. For investigation of bloodbrain barrier permeability in non-manipulated mice 10 mice were used.
Permanent middle cerebral artery occlusion (pMCAO).
Surgical procedure: Mice were subjected to focal cerebral ischemia by permanent occlusion of the middle cerebral artery (MCA), as previously described (29) . Briefly, the animals were anesthetized by subcutaneous injections of 0. injection of 0.9% NaCl.
Physiological parameters.
Physiological parameters were carefully monitored prior to and in the acute phase after pMCAO surgery (first critical 6 hours).
Body weight monitoring:
The body weight of the mouse was registered during pre-training, before surgery, and at 24 and 48 hours after surgery.
Temperature monitoring: The rectal temperature of the mouse was continuously measured using a thermocoupled probe connected to a Model Bat 12 unit (Physitemp). The temperature was measured prior to and 30 min after pMCAO in addition to 30 min and 2.5 hours after i.v.
injection, i.e. 1 and 3 hours after pMCAO.
Blood gas analysis:
One sample of venous blood was taken for blood gas analysis of PO 2 /PCO 2 electrolytes, glucose, lactate, and hematocrit, 30 min after compound administration (1 hour after pMCAO). A capillary heparin coated tube was inserted along the inner corner of eye and turned until it penetrated the conjunctiva. A sample of blood (150 μl) was collected and stored on ice until gas analysis using the GEM Premier 300 blood gas instrument (Instrumentation Laboratory). Quality controls (QC ContrlIL9) were purchased from IL Sensor Systems.
Behavioral tests.
Mice with 48 hours post-surgical survival were examined using three different behavioral tests in order to detect motor deficits that may not necessarily manifest in the infarct size, thereby providing a more general impression of the animal´s condition (30) .
Grip strength: The grip strength meter (BIO-GT-3, BIOSEB) allowed the study of neuromuscular functions in mice by determining the maximum force that is required to make the mouse release its grip. The mouse is allowed to grasp a metal grid and then pulled backwards in the horizontal plane. The force applied to the grid is recorded as the peak tension. Individual (right and left) and total (both) front paw grip strength was measured before (baseline) and after pMCAO. Each mouse was tested in 5 sequential trials and the highest grip strength was recorded as the score (29) .
Rotarod performance test:
The rotarod (LE 8200, Panlab) is well suited to evaluate motor activity in rodents, experimental compound effects on central nervous system damage, or disease UPlanApo) connected to a high-resolution microscope digital camera (Olympus model DP70), which transferred images to an image-capturing software (Image Pro Plus software). All images were taken in reference to sections from saline treated mice using the same microscope settings and with constant camera exposure time. Fluorescence intensities were quantified using the ImageJ 1.42q software.
Statistical analysis. e. R free is equivalent to R work , but calculated with reflections omitted from the refinement process (5 % of reflections omitted). f. Rms = root mean square. g. Ramachandran outliers were calculated according to Kleywegt and Jones (36) h. Domains are divided between Ala97 and Glu98. A1, B1, C1 and D1 correspond to PDZ1 of molecules A, B, C and D, respectively. A2, B2, C2 and D2 correspond to PDZ2 of molecules A, B, C and D, respectively. 
